
82 Revista Médica Vozandes
Volumen 33, Número 2, 2022
Referencias
1. Maguiña C, Gastelo R, Tequen A. The new
Coronavirus and the Covid-19 pandemic.
Rev Medica Hered [Internet]. 2020;31(2):125–
31.doi: 10.20453/rmh.v31i2.3776. Avai-
lable from: http://www.scielo.org.pe/
scielo.php?script=sci_arttext&pid=S1018-
130X2020000200125.
2. Park SY, Yun SG, Shin JW, Lee BY, Son HJ, Lee
S, et al. Persistent severe acute respiratory
syndrome coronavirus 2 detection after reso-
lution of coronavirus disease 2019-associated
symptoms/signs. Korean J Intern Med. 2020
Jul;35(4):793-796. doi: 10.3904/kjim.2020.203.
3. Deer RR, Rock MA, Vasilevsky N, Carmody L,
Rando H, Anzalone AJ, et al. Characterizing
Long COVID: Deep Phenotype of a Complex
Condition. EBioMedicine. 2021 Dec;74:103722.
doi: 10.1016/j.ebiom.2021.103722. Epub 2021
Nov 25.
4. Tejerina F, Garcia D, Gracia MA. Post-CO-
VID-19 or persistent COVID-19 syndrome: a
case with detection of SARS-CoV-2 RNA in
plasma. Med Gen and Fam. 2021;10(2):91–4.
doi: 10.24038/mgyf.2021.022. Available from:
www.mgyf.org
5. Bianchi JL, Martin I, Medrano FJ. Prolon-
ged COVID-19 syndrome: a new cha-
llenge for Internal Medicine. Current
Med. 2020;105(811):253–5. doi: 10.15568/
am.2020.811.ami01.
6. Dos Santos A, Lima A. Covid longa e pos-co-
vid. Subsecr Saúde Gerência Strategic Infor-
mation in Saúde CONECTA-SUS. 2021;02:1–7.
7. Raveendran AV, Jayadevan R, Sashidharan
S. Long COVID: An overview. Diabetes Me-
tab Syndr. 2021 May-Jun;15(3):869-875. doi:
10.1016/j.dsx.2021.04.007. Epub 2021 Apr
20. Erratum in: Diabetes Metab Syndr. 2022
May;16(5):102504.
8. Sykes DL, Holdsworth L, Jawad N, Gunaseke-
ra P, Morice AH, Crooks MG, et al. Post-CO-
VID-19 Symptom Burden: What is Long-COVID
and How Should We Manage It? Lung. 2021
Apr;199(2):113-119. doi: 10.1007/s00408-021-
00423-z.
9. Sudre CH, Murray B, Varsavsky T, Graham MS,
Penfold RS, Bowyer RC, et al. Attributes and
predictors of long COVID. Nat Med. 2021
Apr;27(4):626-631. doi: 10.1038/s41591-021-
01292-y. Epub 2021 Mar 10. Erratum in: Nat
Med. 2021 Jun;27(6):1116.
10. Mandal S, Barnett J, Brill SE, Brown JS, Den-
neny EK, Hare SS, et al. ‘Long-COVID’: a
cross-sectional study of persisting symptoms,
biomarker and imaging abnormalities fo-
llowing hospitalisation for COVID-19. Thorax.
2021 Apr;76(4):396-398. doi: 10.1136/thora-
xjnl-2020-215818. Epub 2020 Nov 10. PMID:
33172844;
11. Townsend L, Dyer AH, Jones K, Dunne J,
Mooney A, Gaffney F, et al. Persistent fatigue
following SARS-CoV-2 infection is common
and independent of severity of initial infec-
tion. PLoS One. 2020 Nov 9;15(11):e0240784.
doi: 10.1371/journal.pone.0240784.
12. Carvalho-Schneider C, Laurent E, Lemaignen
A, Beauls E, Bourbao-Tournois C, Laribi S, et
al. Follow-up of adults with noncritical CO-
VID-19 two months after symptom onset. Clin
Microbiol Infect. 2021 Feb;27(2):258-263. doi:
10.1016/j.cmi.2020.09.052. Epub 2020 Oct 5.
13. Goërtz YMJ, Van Herck M, Delbressine JM,
Vaes AW, Meys R, Machado FVC, et al. Persis-
tent symptoms 3 months after a SARS-CoV-2
infection: the post-COVID-19 syndrome? ERJ
Open Res. 2020 Oct 26;6(4):00542-2020. doi:
10.1183/23120541.00542-2020.
14. Mackay A. A Paradigm for Post-Covid-19 Fa-
tigue Syndrome Analogous to ME/CFS. Front
Neurol. 2021 Aug 2;12:701419. doi: 10.3389/
fneur.2021.701419.
15. Kamal M, Abo Omirah M, Hussein A, Saeed H.
Assessment and characterisation of post-CO-
VID-19 manifestations. Int J Clin Pract. 2021
Mar;75(3):e13746. doi: 10.1111/ijcp.13746.
Epub 2020 Nov 3. PMID: 32991035;
16. Osikomaiya B, Erinoso O, Wright KO, Odusola
AO, Thomas B, Adeyemi O, et al. ‘Long CO-
VID’: persistent COVID-19 symptoms in survi-
vors managed in Lagos State, Nigeria. BMC
Infect Dis. 2021 Mar 25;21(1):304. doi: 10.1186/
s12879-020-05716-x.
17. Stavem K, Ghanima W, Olsen MK, Gilboe HM,
Einvik G. Persistent symptoms 1.5-6 months
after COVID-19 in non-hospitalised subjects:
a population-based cohort study. Thorax.
2021 Apr;76(4):405-407. doi: 10.1136/thora-
xjnl-2020-216377.
18. Varatharaj A, Thomas N, Ellul MA, Davies NWS,
Pollak TA, Tenorio EL, et al. Neurological and
neuropsychiatric complications of COVID-19
in 153 patients: a UK-wide surveillance study.
Lancet Psychiatry. 2020 Oct;7(10):875-882.
doi: 10.1016/S2215-0366(20)30287-X. Epub
2020 Jun 25. Erratum in: Lancet Psychiatry.
2020 Jul 14;:
19. Woo MS, Malsy J, Pöttgen J, Seddiq Zai S, Ufer
F, Hadjilaou A, et al. Frequent neurocognitive
decits after recovery from mild COVID-19.
Brain Commun. 2020 Nov 23;2(2):fcaa205.
doi: 10.1093/braincomms/fcaa205.
20. Rogers JP, Chesney E, Oliver D, Pollak TA,
McGuire P, Fusar-Poli P, et al. Psychiatric and
neuropsychiatric presentations associated
with severe coronavirus infections: a systema-
tic review and meta-analysis with comparison
to the COVID-19 pandemic. Lancet Psychia-
try. 2020 Jul;7(7):611-627. doi: 10.1016/S2215-
0366(20)30203-0.
21. Myall KJ, Mukherjee B, Castanheira AM, Lam
JL, Benedetti G, Mak SM, et al. Persistent Post-
COVID-19 Interstitial Lung Disease. An Obser-
vational Study of Corticosteroid Treatment.
Ann Am Thorac Soc. 2021 May;18(5):799-806.
doi: 10.1513/AnnalsATS.202008-1002OC.
22. Sonnweber T, Sahanic S, Pizzini A, Luger A,
Schwabl C, Sonnweber B, et al. Cardiopul-
monary recovery after COVID-19: an ob-
servational prospective multicentre trial.
Eur Respir J. 2021 Apr 29;57(4):2003481. doi:
10.1183/13993003.03481-2020.
23. Ahmed H, Patel K, Greenwood DC, Halpin
S, Lewthwaite P, Salawu A, et al. Long-term
clinical outcomes in survivors of severe acu-
te respiratory syndrome and Middle East
respiratory syndrome coronavirus outbreaks
after hospitalisation or ICU admission: A sys-
tematic review and meta-analysis. J Reha-
bil Med. 2020 May 31;52(5):jrm00063. doi:
10.2340/16501977-2694.
24. Afrin LB, Weinstock LB, Molderings GJ. Co-
vid-19 hyperinammation and post-Covid-19
illness may be rooted in mast cell activation
syndrome. Int J Infect Dis. 2020 Nov;100:327-
332. doi: 10.1016/j.ijid.2020.09.016. Epub 2020
Sep 10.
25. Huang C, Huang L, Wang Y, Li X, Ren L, Gu
X, et al. 6-month consequences of COVID-19
in patients discharged from hospital: a cohort
study. Lancet. 2021 Jan 16;397(10270):220-
232. doi: 10.1016/S0140-6736(20)32656-8.
26. Verstrepen K, Baisier L, De Cauwer H. Neuro-
logical manifestations of COVID-19, SARS and
MERS. Acta Neurol Belg. 2020 Oct;120(5):1051-
1060. doi: 10.1007/s13760-020-01412-4. Epub
2020 Jul 21. Erratum in: Acta Neurol Belg. 2020
Jul 21:
27. Butowt R, von Bartheld CS. Anosmia in CO-
VID-19: Underlying Mechanisms and As-
sessment of an Olfactory Route to Brain Infec-
tion. Neuroscientist. 2021 Dec;27(6):582-603.
doi: 10.1177/1073858420956905.
28. Wostyn P. COVID-19 and chronic fatigue
syndrome: Is the worst yet to come? Med Hy-
potheses. 2021 Jan;146:110469. doi: 10.1016/j.
mehy.2020.110469.
29. Paterson RW, Brown RL, Benjamin L, Nortley R,
Wiethoff S, Bharucha T, et al. The emerging
spectrum of COVID-19 neurology: clinical, ra-
diological and laboratory ndings. Brain. 2020
Oct 1;143(10):3104-3120. doi: 10.1093/brain/
awaa240.
30. Halpin SJ, McIvor C, Whyatt G, Adams A, Har-
vey O, McLean L, et al. Postdischarge symp-
toms and rehabilitation needs in survivors of
COVID-19 infection: A cross-sectional evalua-
tion. J Med Virol. 2021 Feb;93(2):1013-1022.
doi: 10.1002/jmv.26368.
31. Dani M, Dirksen A, Taraborrelli P, Torocastro M,
Panagopoulos D, Sutton R, et al. Autonomic
dysfunction in ‘long COVID’: rationale, phy-
siology and management strategies. Clin
Med (Lond). 2021 Jan;21(1):e63-e67. doi:
10.7861/clinmed.2020-0896.
32. Ahmed S, Zimba O, Gasparyan AY. COVID-19
and the clinical course of rheumatic manifes-
tations. Clin Rheumatol. 2021 Jul;40(7):2611-
2619. doi: 10.1007/s10067-021-05691-x.
SINTOMATOLOGÍA PERSISTENTE POSTERIOR A
INFECCIÓN POR SARS-COV-2 (...) Saráuz Rivadeneira E